Year: 2025
Type: editorial
Abstract: In this issue of Blood, Giri et al report that sustained minimal residual disease (MRD) negativity at the 10 -5 threshold is the most effective predictor of progression-free survival (PFS) after intensive therapy in patients with newly diagnosed multiple myeloma (NDMM). 1
Source: Blood
Authors: Aurore Perrot, Jill Corre
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4413043509